Lilly to pay $337K for toxic emissions; Savient's Q4 loss widens on Krystexxa launch;

@FiercePharma: Obama fingers FDA as agency in need of overhaul. Item | Follow @FiercePharma

> Eli Lilly has agreed to pay a $337,500 fine to settle a federal complaint that an Indianapolis manufacturing plant released dangerous chemicals into the air during an inspection in 2006. Report

> AstraZeneca has moved its London global headquarters to new, larger premises that will be home to some 350 members of its UK staff, plus another 90 or so relocating from the U.S. and Belgium. News

> Bayer posted its first quarterly loss in seven years on a writedown of the Schering drug brand and said pharmaceutical sales growth isn't likely to match the market this year. Item

> Savient Pharmaceuticals said its fourth-quarter loss widened as costs climbed while the drugmaker prepared for the launch of its gout treatment Krystexxa. Report

> The U.S. Senate is taking up the Patent Reform Act, which would significantly overhaul a 1952 law and, supporters say, bring the patent system in line with 21st century technology of biogenetics and artificial intelligence. Article

> Johnson & Johnson faces the threat of a consumer boycott from campaigners who suffered birth defects 50 years ago caused by the morning sickness drug thalidomide. Story

> A Sioux City, Iowa, bank has filed a personal-injury lawsuit against infant formula maker Abbott Laboratories, claiming a local girl got seriously ill from drinking reconstituted powdered formula days after she was born in 2008. Report

> Takeda Pharmaceutical has won FDA approval to sell a new once-daily pill for adults with high blood pressure. News

> Novartis will begin a second offer period for shares in U.S. cancer diagnostics company Genoptix after securing acceptances for 80 percent in the initial offer. Article

Biotech News

@FierceBiotech: Samsung, Quintiles team on $266M biosimilars deal. News | Follow @FierceBiotech

@JohnCFierce: Protalix shares still down 35% Friday morning. They were expecting an approval  | Follow @JohnCFierce 

> Sangamo sees signs of efficacy for HIV treatment. Report 

> Aggressive midcap biotechs suit up for the M&A game. Story 

> FDA spurns Pharming's Rhucin app in fresh setback. News 

Biotech IT

> Merck checks out tablets for R&D. Report 

> OpenClinica update is user-driven. Article 

> EDC differentiation getting hard to see. Item

Medical Devices News

> Nile, Medtronic partner on heart failure therapy. Story

> Hologic gets win in ongoing dispute with SenoRx. News 

> Epigenomics, Qiagen enter colorectal cancer test agreement. Report 

> Medtronic cancels $2B Novation pact. Story

And Finally... Scientists have shown that they can deliver a gene directly into breast cancer cells, causing them to self-destruct. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.